Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Current Leases (2019 - 2025)

Historic Current Leases for Abvc Biopharma (ABVC) over the last 7 years, with Q3 2025 value amounting to $199335.0.

  • Abvc Biopharma's Current Leases fell 4545.61% to $199335.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $199335.0, marking a year-over-year decrease of 4545.61%. This contributed to the annual value of $403581.0 for FY2024, which is 43.68% up from last year.
  • Per Abvc Biopharma's latest filing, its Current Leases stood at $199335.0 for Q3 2025, which was down 4545.61% from $282192.0 recorded in Q2 2025.
  • Over the past 5 years, Abvc Biopharma's Current Leases peaked at $403581.0 during Q4 2024, and registered a low of $199335.0 during Q3 2025.
  • Over the past 5 years, Abvc Biopharma's median Current Leases value was $365458.0 (recorded in 2024), while the average stood at $355125.2.
  • Its Current Leases has fluctuated over the past 5 years, first surged by 5355.78% in 2021, then tumbled by 4545.61% in 2025.
  • Abvc Biopharma's Current Leases (Quarter) stood at $347100.0 in 2021, then grew by 6.4% to $369314.0 in 2022, then increased by 8.8% to $401826.0 in 2023, then rose by 0.44% to $403581.0 in 2024, then crashed by 50.61% to $199335.0 in 2025.
  • Its Current Leases stands at $199335.0 for Q3 2025, versus $282192.0 for Q2 2025 and $366475.0 for Q1 2025.